Short-acting Insulin Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Report Covers Short-Acting Insulin Market Size & Major Brands and is Segmented by Drug (Apidra (Glulisine), Novolog/novorapid, Humalog (Lispro), Novolin (Actrapid), Insuman, Humulin, Fiasp, And Admelog) and Geography (North America, Europe, Latin America, Asia Pacific, And Middle-East and Africa). The Market Size and Forecasts are Provided in Terms of Value (in USD) and Volume (in Units) for the Above Segments.

Short-acting Insulin Market Size

Compare market size and growth of Short-acting Insulin Market with other markets in Healthcare Industry

Short-acting Insulin Market Analysis

The Short-acting Insulin Market size is estimated at USD 7.48 billion in 2025, and is expected to reach USD 8.87 billion by 2030, at a CAGR of 3.46% during the forecast period (2025-2030).

There is not enough data saying that diabetes people are more likely to get COVID-19 than other healthy people, individuals with any kind of diabetes might differ in age, the number of complications they have had, and their level of diabetes management. Whatever kind of diabetes a person has, those who currently have diabetes-related health issues are more likely to experience poorer results if they get COVID-19. Leading suppliers of insulin drugs claim that at the moment, COVID-19 is not affecting their present capacity for producing and distributing products like insulin.

When a person has type 1 diabetes, their pancreas stops producing insulin. They require insulin injections to utilize the glucose from meals since their beta cells have been damaged.

Insulin is produced by people with type 2 diabetes, but their bodies do not respond effectively to it. Some patients with type 2 diabetes require insulin injections or diabetic medications to help their bodies utilize glucose as fuel. Insulin would be broken down during digestion, much like the protein in food, insulin cannot be given orally, to enter the bloodstream, it must be injected into the fat beneath the skin.

Currently, there are five main types of insulins (regular insulin, NPH, short-acting analogs, basal analogs, and pre-mixed insulin) being sold globally. Generally, insulin analogs are priced much higher than regular insulin or NPH, as they are bioengineered with altered amino-acid sequences to provide the desired chemical properties. In recent days, usage of short-acting analogs has been increasing due to the increasing Type 1 diabetes population.

Thus, owing to the above factors it is expected to drive the market growth over the forecast period.

Short-acting Insulin Industry Overview

The Short-Acting Insulin Market is highly consolidated, with leading companies like Sanofi, Novo Nordisk, and Eli Lilly, having a strong market presence. Each of these companies has established its brands in the market. However, due to intense competition in the local markets, these manufacturers put a lot of effort into penetrating these markets. Hence, they employ powerful competitive strategies to improve their foothold in the market. Additionally, the high profitability of the market provides an incentive for several generic insulins (biosimilars) manufacturers and major companies trying to introduce innovative products.

Short-acting Insulin Market Leaders

  1. Eli Lilly

  2. Sanofi Aventis

  3. Novo Nordisk AS

  4. Pfizer

  5. Biocon

  6. *Disclaimer: Major Players sorted in no particular order
Need More Details on Market Players and Competitors?
Download PDF

Short-acting Insulin Market News

  • March 2023: Eli Lilly and Company announced price reductions of 70% for its most commonly prescribed insulins and an expansion of its Insulin Value Program that caps patient out-of-pocket costs at USD 35 or less per month. Lilly is taking these actions to make it easier to access Lilly insulin and help Americans who may have difficulty navigating a complex healthcare system that may keep them from getting affordable insulin.
  • May 2022: the U.S. Food and Drug Administration has authorized Mounjaro (tirzepatide) injectables to help individuals with type 2 diabetes better regulate their blood sugar levels. In clinical investigations, Mounjaro was compared to other diabetic treatments and shown to be more effective at lowering blood sugar.

Short-acting Insulin Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET INSIGHTS

  • 4.1 Market Overview
  • 4.2 Market Drivers
  • 4.3 Market Restraints
  • 4.4 Industry Attractiveness - Porter's Five Forces Analysis
    • 4.4.1 Bargaining Power of Suppliers
    • 4.4.2 Bargaining Power of Consumers
    • 4.4.3 Threat of New Entrants
    • 4.4.4 Threat of Substitute Products and Services
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION

  • 5.1 Drug
    • 5.1.1 Short-acting Insulins
    • 5.1.1.1 Apidra (Glulisine)
    • 5.1.1.2 Novolog/Novorapid
    • 5.1.1.3 Humalog (Lispro)
    • 5.1.1.4 Novolin (Actrapid)
    • 5.1.1.5 Insuman
    • 5.1.1.6 Humulin
    • 5.1.1.7 FIASP
    • 5.1.1.8 Admelog
  • 5.2 Geography
    • 5.2.1 North America
    • 5.2.1.1 United States
    • 5.2.1.2 Canada
    • 5.2.1.3 Rest of North America
    • 5.2.2 Europe
    • 5.2.2.1 United Kingdom
    • 5.2.2.2 Germany
    • 5.2.2.3 France
    • 5.2.2.4 Italy
    • 5.2.2.5 Spain
    • 5.2.2.6 Russia
    • 5.2.2.7 Rest of Europe
    • 5.2.3 Latin America
    • 5.2.3.1 Mexico
    • 5.2.3.2 Brazil
    • 5.2.3.3 Rest of Latin America
    • 5.2.4 Asia-Pacific
    • 5.2.4.1 Japan
    • 5.2.4.2 South Korea
    • 5.2.4.3 China
    • 5.2.4.4 India
    • 5.2.4.5 Australia
    • 5.2.4.6 Vietnam
    • 5.2.4.7 Malaysia
    • 5.2.4.8 Indonesia
    • 5.2.4.9 The Philippines
    • 5.2.4.10 Thailand
    • 5.2.4.11 Rest of Asia-Pacific
    • 5.2.5 Middle-East and Africa
    • 5.2.5.1 Saudi Arabia
    • 5.2.5.2 Iran
    • 5.2.5.3 Egypt
    • 5.2.5.4 Oman
    • 5.2.5.5 South Africa
    • 5.2.5.6 Rest of Middle-East and Africa

6. MARKET INDICATORS

  • 6.1 Type-1 Diabetes Population
  • 6.2 Type-2 Diabetes Population

7. COMPETITIVE LANDSCAPE

  • 7.1 Company Profiles
    • 7.1.1 Novo Nordisk AS
    • 7.1.2 Sanofi Aventis
    • 7.1.3 Eli Lilly
    • 7.1.4 Pfizer
    • 7.1.5 Biocon
  • *List Not Exhaustive
  • 7.2 Company Share Analysis
    • 7.2.1 Novo Nordisk AS
    • 7.2.2 Sanofi Aventis
    • 7.2.3 Eli Lilly
    • 7.2.4 Other Companies

8. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
*We will provide a segment-wise breakdown (Value and Volume) for all the countries covered under the Table of Contents. **Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Short-acting Insulin Industry Segmentation

Regular insulin is short-acting human-made insulin. It helps adults and children with Type 1 and Type 2 diabetes control their blood sugar levels. Take regular insulin 30 minutes before eating a meal. Short-Acting Insulin Market is segmented by Drug (Apidra (Glulisine), Novolog/Novorapid, Humalog (Lispro), Novolin (Actrapid), Insuman, Humulin, FIASP, and Admelog) and Geography (North America, Europe, Latin America, Asia Pacific, and Middle-East and Africa). 

Drug Short-acting Insulins Apidra (Glulisine)
Novolog/Novorapid
Humalog (Lispro)
Novolin (Actrapid)
Insuman
Humulin
FIASP
Admelog
Geography North America United States
Canada
Rest of North America
Europe United Kingdom
Germany
France
Italy
Spain
Russia
Rest of Europe
Latin America Mexico
Brazil
Rest of Latin America
Asia-Pacific Japan
South Korea
China
India
Australia
Vietnam
Malaysia
Indonesia
The Philippines
Thailand
Rest of Asia-Pacific
Middle-East and Africa Saudi Arabia
Iran
Egypt
Oman
South Africa
Rest of Middle-East and Africa
Need A Different Region or Segment?
Customize Now

Short-acting Insulin Market Research FAQs

How big is the Short-acting Insulin Market?

The Short-acting Insulin Market size is expected to reach USD 7.48 billion in 2025 and grow at a CAGR of 3.46% to reach USD 8.87 billion by 2030.

What is the current Short-acting Insulin Market size?

In 2025, the Short-acting Insulin Market size is expected to reach USD 7.48 billion.

Who are the key players in Short-acting Insulin Market?

Eli Lilly, Sanofi Aventis, Novo Nordisk AS, Pfizer and Biocon are the major companies operating in the Short-acting Insulin Market.

Which is the fastest growing region in Short-acting Insulin Market?

Middle-East and Africa is estimated to grow at the highest CAGR over the forecast period (2025-2030).

Which region has the biggest share in Short-acting Insulin Market?

In 2025, the North America accounts for the largest market share in Short-acting Insulin Market.

What years does this Short-acting Insulin Market cover, and what was the market size in 2024?

In 2024, the Short-acting Insulin Market size was estimated at USD 7.22 billion. The report covers the Short-acting Insulin Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Short-acting Insulin Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Short-acting Insulin Industry Report

Statistics for the 2025 Short-acting Insulin market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Short-acting Insulin analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.

Short-acting Insulin Market Report Snapshots

Short-acting Insulin Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)